183 related articles for article (PubMed ID: 3044574)
1. Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line.
Eisbruch A; Blick M; Evinger-Hodges MJ; Beran M; Andersson B; Gutterman JU; Kurzrock R
Cancer; 1988 Sep; 62(6):1171-8. PubMed ID: 3044574
[TBL] [Abstract][Full Text] [Related]
2. Induction of erythroid differentiation by 5-fluorouracil in K562 leukemia cells.
Yang YW; Chang YH
Jpn J Cancer Res; 1995 Oct; 86(10):948-55. PubMed ID: 7493914
[TBL] [Abstract][Full Text] [Related]
3. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
4. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
5. Alpha-interferon reduces in vivo phosphorylation of P210bcr/abl protein during hemin-induced erythroid differentiation of K-562 cells.
Shibata K; Nishimura J; Takahira H; Nawata H
Exp Hematol; 1991 Mar; 19(3):161-5. PubMed ID: 1995306
[TBL] [Abstract][Full Text] [Related]
6. The bcr-c-abl tyrosine kinase activity is extinguished by TPA in K562 leukemia cells.
Alitalo R
FEBS Lett; 1987 Oct; 222(2):293-8. PubMed ID: 3477472
[TBL] [Abstract][Full Text] [Related]
7. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
Ray S; Bullock G; Nuñez G; Tang C; Ibrado AM; Huang Y; Bhalla K
Cell Growth Differ; 1996 Dec; 7(12):1617-23. PubMed ID: 8959329
[TBL] [Abstract][Full Text] [Related]
8. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
[TBL] [Abstract][Full Text] [Related]
9. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
Andersson BS; Collins VP; Kurzrock R; Larkin DW; Childs C; Ost A; Cork A; Trujillo JM; Freireich EJ; Siciliano MJ
Leukemia; 1995 Dec; 9(12):2100-8. PubMed ID: 8609723
[TBL] [Abstract][Full Text] [Related]
10. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia.
Kurzrock R; Kloetzer WS; Talpaz M; Blick M; Walters R; Arlinghaus RB; Gutterman JU
Blood; 1987 Jul; 70(1):233-6. PubMed ID: 2885048
[TBL] [Abstract][Full Text] [Related]
11. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
12. The molecular pathology of chronic myelogenous leukaemia.
Kurzrock R; Talpaz M
Br J Haematol; 1991 Oct; 79 Suppl 1():34-7. PubMed ID: 1931706
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of erythroid differentiation by stem cell factor in K562 cells expressing the c-kit gene.
Ogawa K; Tashima M; Toi T; Sawai H; Sawada H; Fujita J; Maruyama Y; Okuma M
Exp Hematol; 1994 Jan; 22(1):45-51. PubMed ID: 7506674
[TBL] [Abstract][Full Text] [Related]
14. Effects of the antisense myb expression on hemin- and erythropoietin-induced erythroid differentiation of K562 cells.
Kamano H; Tanaka T; Ohnishi H; Kubota Y; Ikeda K; Takahara J; Irino S; Ottalenghi S
Biochem Mol Biol Int; 1994 Aug; 34(1):85-92. PubMed ID: 7849628
[TBL] [Abstract][Full Text] [Related]
15. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
16. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
17. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
Dilloo D; Hanenberg H; Lion T; Burdach S
Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia.
Kurzrock R; Shtalrid M; Talpaz M; Kloetzer WS; Gutterman JU
Blood; 1987 Nov; 70(5):1584-8. PubMed ID: 3311207
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of tumor promoters on P210bcr-abl expression.
Li WJ; Smith LA; Kabat KG; Kloetzer WS; Arlinghaus RB
Hematol Pathol; 1989; 3(3):113-23. PubMed ID: 2687223
[TBL] [Abstract][Full Text] [Related]
20. A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells.
Li WJ; Kloetzer WS; Arlinghaus RB
Oncogene; 1988 Jun; 2(6):559-66. PubMed ID: 3133627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
